US 12,421,497 B2
Method for enriching cardiac myocytes
Yoshinori Yoshida, Kyoto (JP); Kenji Miki, Kyoto (JP); and Misato Koakutsu, Kyoto (JP)
Assigned to Orizuru Therapeutics, Inc., Kanagawa (JP)
Appl. No. 17/636,561
Filed by Orizuru Therapeutics, Inc., Fujisawa (JP)
PCT Filed Aug. 19, 2020, PCT No. PCT/JP2020/031194
§ 371(c)(1), (2) Date Feb. 18, 2022,
PCT Pub. No. WO2021/033699, PCT Pub. Date Feb. 25, 2021.
Claims priority of application No. 2019-150593 (JP), filed on Aug. 20, 2019; and application No. 2020-059409 (JP), filed on Mar. 30, 2020.
Prior Publication US 2022/0298482 A1, Sep. 22, 2022
Int. Cl. C12N 5/077 (2010.01)
CPC C12N 5/0657 (2013.01) [C12N 2500/24 (2013.01); C12N 2500/32 (2013.01); C12N 2501/115 (2013.01); C12N 2501/155 (2013.01); C12N 2501/16 (2013.01); C12N 2501/165 (2013.01); C12N 2506/45 (2013.01)] 4 Claims
 
1. A method for enriching atrial myocytes or ventricular myocytes in a cardiomyocyte-containing cell population induced from stem cells, comprising a step of enriching atrial myocytes by removing a cell subpopulation identified by CD151-high expression from the cardiomyocyte-containing cell population or by collecting a cell subpopulation identified by CD151-low expression from the cardiomyocyte-containing cell population, or enriching ventricular myocytes by removing a cell subpopulation identified by CD151-low expression from the cardiomyocyte-containing cell population or by collecting a cell subpopulation identified by CD151-high expression from the cardiomyocyte-containing cell population.